4/27, 4:25 PM (Source: TeleTrader)
more TeleTrader news


Chart for: Pfizer Inc

Pfizer CEO: Oral drug for COVID may be ready by 2022

Pfizer's Chief Executive Officer Albert Bourla (pictured) said on Tuesday that an oral antiviral drug for preventing the coronavirus could be ready by the end of the year "if all goes well."

Speaking to CNBC, Bourla explained that the company has been making progress in its clinical studies of the small-molecule drug and that he expects drug regulators will act quickly once it has been fully tested. He added that Pfizer will update the public on the drug's progress "around the summer."

Gilead Sciences' remdesivir is currently the only antiviral drug approved in the United States for COVID-19.

Breaking the News / JC